| Dr Christopher Charles Paredes, MD | |
|
1983 Marcus Ave, Suite C102, New Hyde Park, NY 11042-2000 | |
| (516) 876-4100 | |
| Not Available |
| Full Name | Dr Christopher Charles Paredes |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 15 Years |
| Location | 1983 Marcus Ave, New Hyde Park, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467707646 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207QG0300X | Family Medicine - Geriatric Medicine | 270465 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Vns Of Ny Home Care Chha | New york, NY | Home health agency |
| North Shore Home Care Chha | Westbury, NY | Home health agency |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| North Shore-lij Medical Group Pc | 3971878901 | 16 |
News Archive
VBL Therapeutics today announced the initiation of a Phase 2 efficacy and safety study evaluating lead compound VB-201 for the treatment of patients with psoriasis. VB-201 is poised to be a first-in-class, orally-administered immune response modifier expected to reduce inflammation in a broad range of conditions such as psoriasis.
Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2009. For the three months ended December 31, 2009, Alexion Pharmaceuticals, Inc. ("Alexion" or, the "Company") reported net product sales of Soliris® (eculizumab) of $110.6 million, reflecting strong additions of new patients, compared to $77.4 million for the same period in 2008.
The protein clumping is part of a "vicious cycle," the researchers said. As the proteins cluster, they inhibit an enzyme that normally breaks them down, leading to the formation of even more masses.
The Black Death swept Europe in the 14th century eliminating up to half of the population but it left genetic clues that now may aid a University of Cincinnati researcher in treating HIV patients co-infected with hepatitis C using an anti-retroviral drug therapy.
› Verified 3 days ago
| Entity Name | Montefiore Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063525152 PECOS PAC ID: 3779496021 Enrollment ID: O20031113000235 |
News Archive
VBL Therapeutics today announced the initiation of a Phase 2 efficacy and safety study evaluating lead compound VB-201 for the treatment of patients with psoriasis. VB-201 is poised to be a first-in-class, orally-administered immune response modifier expected to reduce inflammation in a broad range of conditions such as psoriasis.
Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2009. For the three months ended December 31, 2009, Alexion Pharmaceuticals, Inc. ("Alexion" or, the "Company") reported net product sales of Soliris® (eculizumab) of $110.6 million, reflecting strong additions of new patients, compared to $77.4 million for the same period in 2008.
The protein clumping is part of a "vicious cycle," the researchers said. As the proteins cluster, they inhibit an enzyme that normally breaks them down, leading to the formation of even more masses.
The Black Death swept Europe in the 14th century eliminating up to half of the population but it left genetic clues that now may aid a University of Cincinnati researcher in treating HIV patients co-infected with hepatitis C using an anti-retroviral drug therapy.
› Verified 3 days ago
| Entity Name | North Shore - Lij Medical Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053688572 PECOS PAC ID: 3375701568 Enrollment ID: O20120220000262 |
News Archive
VBL Therapeutics today announced the initiation of a Phase 2 efficacy and safety study evaluating lead compound VB-201 for the treatment of patients with psoriasis. VB-201 is poised to be a first-in-class, orally-administered immune response modifier expected to reduce inflammation in a broad range of conditions such as psoriasis.
Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2009. For the three months ended December 31, 2009, Alexion Pharmaceuticals, Inc. ("Alexion" or, the "Company") reported net product sales of Soliris® (eculizumab) of $110.6 million, reflecting strong additions of new patients, compared to $77.4 million for the same period in 2008.
The protein clumping is part of a "vicious cycle," the researchers said. As the proteins cluster, they inhibit an enzyme that normally breaks them down, leading to the formation of even more masses.
The Black Death swept Europe in the 14th century eliminating up to half of the population but it left genetic clues that now may aid a University of Cincinnati researcher in treating HIV patients co-infected with hepatitis C using an anti-retroviral drug therapy.
› Verified 3 days ago
| Entity Name | North Shore-lij Medical Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942666557 PECOS PAC ID: 3971878901 Enrollment ID: O20171002001431 |
News Archive
VBL Therapeutics today announced the initiation of a Phase 2 efficacy and safety study evaluating lead compound VB-201 for the treatment of patients with psoriasis. VB-201 is poised to be a first-in-class, orally-administered immune response modifier expected to reduce inflammation in a broad range of conditions such as psoriasis.
Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2009. For the three months ended December 31, 2009, Alexion Pharmaceuticals, Inc. ("Alexion" or, the "Company") reported net product sales of Soliris® (eculizumab) of $110.6 million, reflecting strong additions of new patients, compared to $77.4 million for the same period in 2008.
The protein clumping is part of a "vicious cycle," the researchers said. As the proteins cluster, they inhibit an enzyme that normally breaks them down, leading to the formation of even more masses.
The Black Death swept Europe in the 14th century eliminating up to half of the population but it left genetic clues that now may aid a University of Cincinnati researcher in treating HIV patients co-infected with hepatitis C using an anti-retroviral drug therapy.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christopher Charles Paredes, MD 1983 Marcus Ave, Suite C102, New Hyde Park, NY 11042-2000 Ph: (516) 876-4100 | Dr Christopher Charles Paredes, MD 1983 Marcus Ave, Suite C102, New Hyde Park, NY 11042-2000 Ph: (516) 876-4100 |
News Archive
VBL Therapeutics today announced the initiation of a Phase 2 efficacy and safety study evaluating lead compound VB-201 for the treatment of patients with psoriasis. VB-201 is poised to be a first-in-class, orally-administered immune response modifier expected to reduce inflammation in a broad range of conditions such as psoriasis.
Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2009. For the three months ended December 31, 2009, Alexion Pharmaceuticals, Inc. ("Alexion" or, the "Company") reported net product sales of Soliris® (eculizumab) of $110.6 million, reflecting strong additions of new patients, compared to $77.4 million for the same period in 2008.
The protein clumping is part of a "vicious cycle," the researchers said. As the proteins cluster, they inhibit an enzyme that normally breaks them down, leading to the formation of even more masses.
The Black Death swept Europe in the 14th century eliminating up to half of the population but it left genetic clues that now may aid a University of Cincinnati researcher in treating HIV patients co-infected with hepatitis C using an anti-retroviral drug therapy.
› Verified 3 days ago
Yelena Pyatov, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 27005 76th Ave, Department Of Pediatrics, New Hyde Park, NY 11040 Phone: 718-470-7700 | |
Claudine A Smith, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 3000 Marcus Ave Ste 2w15, New Hyde Park, NY 11042 Phone: 855-201-4988 | |
Amber Haq, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Dakota Dr, New Hyde Park, NY 11042 Phone: 516-622-6000 | |
Boahen Owusu Kwakye, AGNP Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3000 Marcus Ave Ste 2w15, New Hyde Park, NY 11042 Phone: 855-201-4988 | |
Martha Arden, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2001 Marcus Ave, Suite N204, New Hyde Park, NY 11042 Phone: 347-882-1321 | |
Mrs. Adelina Fazilov, FNP Family Medicine Medicare: Medicare Enrolled Practice Location: 450 Lakeville Rd, New Hyde Park, NY 11042 Phone: 516-487-9454 Fax: 516-487-2745 | |
Dr. Anam Sarfaraz, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1991 Marcus Ave, 2nd Floor, New Hyde Park, NY 11042 Phone: 516-354-1600 Fax: 516-941-4677 |